These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23088870)

  • 1. HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer.
    McConkey DJ; White M; Yan W
    Adv Cancer Res; 2012; 116():131-63. PubMed ID: 23088870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of tumor cells by targeting histone deacetylases.
    Perego P; Zuco V; Gatti L; Zunino F
    Biochem Pharmacol; 2012 Apr; 83(8):987-94. PubMed ID: 22120677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
    Ruggeri B; Miknyoczki S; Dorsey B; Hui AM
    Adv Pharmacol; 2009; 57():91-135. PubMed ID: 20230760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of proteasome inhibitor action and resistance in cancer.
    McConkey DJ; Zhu K
    Drug Resist Updat; 2008; 11(4-5):164-79. PubMed ID: 18818117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
    Mei S; Ho AD; Mahlknecht U
    Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase 6 in health and disease.
    Seidel C; Schnekenburger M; Dicato M; Diederich M
    Epigenomics; 2015; 7(1):103-18. PubMed ID: 25687470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance to histone deacetylase inhibitors.
    Lee JH; Choy ML; Marks PA
    Adv Cancer Res; 2012; 116():39-86. PubMed ID: 23088868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitors.
    Chan AM; Mitchell A; Grogan L; Shapiro P; Fletcher S
    Bioorg Med Chem; 2024 Apr; 104():117680. PubMed ID: 38582047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy.
    Botrugno OA; Robert T; Vanoli F; Foiani M; Minucci S
    Clin Cancer Res; 2012 May; 18(9):2436-42. PubMed ID: 22512979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
    Batchu SN; Brijmohan AS; Advani A
    Clin Sci (Lond); 2016 Jun; 130(12):987-1003. PubMed ID: 27154743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors: molecular mechanisms of action.
    Xu WS; Parmigiani RB; Marks PA
    Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
    Li G; Jiang H; Chang M; Xie H; Hu L
    J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.